Home / Transcripts / Demant A/S (DEMANT) · November 4, 2026

Demant A/S (DEMANT) Earnings Call Transcript

November 4, 2026

CPSE DK Health Care Health Care Equipment and Supplies interim_update 41 min

Earnings Call Speaker Segments

Peter Pudselykke executive
#1

Good afternoon, everyone, and welcome to the conference call for Demant's interim management statement for Q3 2026. My name is Peter Pudselykke, and I'm heading up the Investor Relations activities here in Demant. With me here today, I have the usual Demant representatives, our President and CEO, Soren Nielsen; our CFO, Rene Schneider; as well as one of my good colleagues in the IR team, Gustav Hoegh. As you should have seen by now, we released the full management statement last evening, and we'll be discussing that during today's call. You should now also be able to find the presentation on our website. The plan for the session is to kick off with the presentation, and we'll follow that up by a Q&A Session. We do expect the total session to last no more than 1 hour, including Q&A. As always, please do pay notice to the disclaimer on Slide #2. And just before we kick off the presentation, please allow me to remind you that we are hosting our Capital Markets Day here in a couple of weeks' time in Copenhagen on November 24. If you have not signed up yet, please do reach out to Christine or myself, and we'll be happy to help you out. And with that, on Slide #4, and I'll leave that to Soren to kick off the presentation with the agenda. Soren?

Søren Nielsen executive
#2

Thank you very much, Peter, and welcome, everybody. I'll go through business highlights and key financial takeaways. I will elaborate a bit more on the individual business areas. I will reiterate but nothing new, our outlook for 2026, and then we'll go into Q&A. Q3, and you have had most of the numbers already, but still let's repeat that Demant in Q3 '26 delivered revenue growth of 21%. This was fueled by very strong organic growth in the Hearing Aids business of 17% and supported by Hearing Aids market that grew 7% in value in Q2. It, of course, also comes from the acquisitive element of KIND, as we are also going to get back to. As announced on October 9, we upgraded our financial outlook for 2026 based on the strong sales numbers in Q3 to an expected full year organic growth of 7% to 8% and an EBIT before special items of DKK 4.7 billion to DKK 5.0 billion. And we have resumed our share buyback program in Q4, expecting to buy a share worth of DKK 3 billion by the end of '27. The highly successful launch of Oticon Reveal has further accelerated the positive momentum that Oticon Zeal created. This is the main driver for the strong results in Hearing Aids, and it confirms the strength and relevance of our product portfolio to customers. And Hearing Care delivered solid organic growth with, of course, a significant acquisitive element and Diagnostics also delivered in line with expectations. So key financial takeaways for Q3, very strong Group organic growth of 11%, additional 10% from acquisitions totaling 21% reported growth. Demant does not disclose for the quarter, but see gross margin increase significantly year-over-year, and ahead of our expectations. This is driven by average selling price in the Hearing Aids business following the successful launch of Oticon Reveal, and I would say also the growth in U.S., North America as well as the acquisition of KIND in Hearing Care. OpEx saw organic growth in line with expectations as we continue to invest in the business while maintaining focus on cost management, then things are totally in line with expectations. Due to the strong organic growth, the Group saw significant operating leverage and therefore, improved EBIT before special items when comparing to the third quarter of '25. We continue to deliver very strong cash flows and gearing multiples have, therefore, declined meaningfully compared to Q2 '26. And as already iterated, we upgraded our outlook for the year on October 9. And business area color review. Hearing Aids market, third quarter, we estimate that the total Hearing Aids market grew around 7% in value. We estimate the underlying unit growth to be 6% in the quarter, and this is with the normal data points, meaning 2/3 of the market we have data for and the rest is an estimation. So a solid unit growth. Also, if you include a contribution from the many product introductions we saw in Q3, we estimate to be around 1%. Of course, not something we have exact insights into, but that's our best take. So underlying, also healthy 5% unit growth. And therefore, year-to-date, we end at 4% unit growth and with a positive ASP component, which brings us into the normal range for the Hearing Aids market of 4% to 6%. By geography, growth in Europe, as you can see also from the table, was strong and good, driven by Germany and France. Market growth in U.K. have improved in the third quarter after 2 quarters with negative growth. This is both the private and the NHS, but most importantly, the NHS returning to growth. Growth in North America was driven primarily, as you can see, by the commercial market in U.S. growing 8%, whereas VA is still a relatively low growth rates in volume and this is in color also a continued negative development to the managed care market. The rest of the world, we estimate unit growth to be around 4%, and that's relatively broad-based across several markets. And we also estimate that China and Japan delivered some growth. Hearing Aids payment in Q3 '26, again, a very strong growth driven by a very successful launch of Oticon Reveal. We are definitely strong out of the gate and around the world quite fast. That's a significant part of it, but it's also clear that we get a very favorable feedback from customers that have now fitted instruments. And we see this as definitely a confirmation that we have released a strong product into the market, not that it's potentially the only one, but that is a strong and competitive product we have brought in. So organic growth of 17%, significantly above expectations, even though we see a slight tougher comps than we did in the second quarter. And the unit growth is above underlying market growth, and therefore, we take significant market share, both in units and value. And strong contributors to growth have been U.K., Germany and France, and Europe, 3 biggest markets, but also a number of medium-sized markets have also contributed. North America, we have seen double-digit organic growth in U.S. coming from both the independent sector as well as VA, slightly positive growth in Canada. Strong growth in Asia despite negative growth in China and very strong growth in Australia as well as solid growth in the rest of the world region. Hearing Care, Q3, solid organic growth and significant contribution, of course, from KIND, broad-based organic growth of 6%, slightly ahead of our expectations, driven by both unit growth and also here some ASP effect also coming from successful introduction of new technology. 29% reported growth, including 22% acquisitive growth where KIND is the main contributor, but also other acquisitions, of course, is part of that. And then we have announced now internally and now also here today that we have started the process to unite all our Hearing Care activities in Germany into one organization and under one brand, the KIND brand will create one hearing care organization in Germany, just as we do in all other markets and the trusted KIND name will be used, but it will come into a Demant virtual identity, and visual identity and you could say, general brand position, so it integrates well with all the business we drive around the world. In growth across the world, solid organic growth driven in Europe, driven by a strong performance in Germany and solid contribution from a number of other medium-sized markets. Strong organic growth driven by continued momentum in Canada and North America and also solid growth in U.S. supported by improved market conditions, but also a continued improvement of our own operating model. Solid broad-based organic growth in the Pacific region, slightly positive growth in Asia, however, with China realizing negative growth. Diagnostics in Q3, organic growth in line with expectation, positive organic growth in Europe, positive organic growth driven by U.S. and North America, negative growth in Canada following a very strong performance in first half. These are the natural things we see. So nothing special to flag there and strong growth in the Pacific region and in rest of the world, driven by Australia and Latin America, whereas it has been more flattish in Asia. Outlook for 2026. There are very few changes. And on this one, bolded as expected, we have seen a refund of tariffs related to U.S. in Q3, and that constitute approximately DKK 25 million. There are still tariffs paid, but we got a significant return in the third quarter. So then coming to the outlook in total, again, nothing new, organic growth of 7% to 8%; EBIT before special items of DKK 4.7 billion to DKK 5.0 billion; share buyback at least DKK 3 billion by the end of 2027 and starting here in the fourth quarter of this year. Acquisitive growth, 9% based on revenue from acquisitions completed as of 2 days ago. And then FX, minus 1% on exchange rate also updated. And then special items, no change DKK 400 million and effective tax rate around 23%. And with that, let's go to the Q&A.

Operator operator
#3

We will now begin the Question-and-Answer Session. [Operator Instructions] The first question comes from Martin Parkhoi with SEB.

Martin Parkhoi analyst
#4

Martin Parkhoi from SEB. Just a question, Soren, on the assumption on the impact from the launches in the third quarter. One of your, should I call it, peers from Italy was maybe a little bit more bearish on the underlying market growth. Can you speak into how scientific you have been in the 1% impact on a global level. Is it based on what you have seen in your own sales? And should I assume that it predominantly has been in the U.S. private pay market that have been affected by this potential roll-in? And then secondly, just on Oticon Reveal or you can call OT Reveal or Philips 9060 inclusion in Costco. Do you see this as an opportunity to further gain market share in Costco? Or is this just a way to maintain the position you have now?

Søren Nielsen executive
#5

We only have our own data and we don't have sell-through data from customers. So it's not an overly scientific exercise to come to the around 1%. But of course, you know what the underlying natural market is. You can see a little bit of peak. Are you fitting more to existing users in that period? Yes. Are people busy getting things out in trial and invoicing? Yes. So it is our best judgment. There's not a bigger scientific element to it. And yes, we believe the majority comes from U.S. based on our data, whether others have launched differently around the world. We sense that a little bit. Some have been focused on Europe, some have others. So it's super difficult to have other than a very rough estimate for the world. And then Philips in Costco, yes, that's definitely part of working to grow our share in Costco. We have been open that we have had a stable business, but a slight loss of share as new players have entered and a new product like Philips 960 is a good opportunity, of course, to gain back some of that share.

Martin Parkhoi analyst
#6

Can I just come with a follow-up question to the market development because we have seen a quite benign development in ASP for the market this year, of course, also supported by strong U.S. and particularly here in the third quarter. If we look at your midterm targets for the market, you have embedded a flat pricing development. Would you see 2026 constitute as a tough comparison going into 2027, not with respect to volumes on the market side, but more respect to the pricing side of the global market?

Søren Nielsen executive
#7

No, not really. Of course, there will always be mix effects going forward. Isolated to Q3, we will have created strong comps, no doubt about that. But for the full year, no, I can't see that.

Martin Parkhoi analyst
#8

Okay, thank you.

Operator operator
#9

The next question comes from the line of Julien Ouaddour with Bank of America.

Julien Ouaddour analyst
#10

Sorry, I joined late, so if I ask something which has already been asked sorry for that. The first one, I'm just wondering the 10% growth difference between retail and wholesale in 3Q, and I was wondering what are your expectations in terms of pure share gains and some sort of stocking maybe on the sell-in with the launch? And do you expect some sort of stocking also to continue into 4Q, maybe something you've seen in October already? And I want to push you maybe on next year for the Hearing Aids market growth for 2027. I mean if we think that maybe 3Q had some launch stocking, I mean they will have tough comps from 2H 2026. Do you expect maybe a slowdown in sell-in in 1Q? And like overall, do you think the market will grow below the 4% to 5% that you assume for 2026?

Søren Nielsen executive
#11

On the sell-in and the difference between retail and wholesale, that is the core difference between the 2 businesses. Of course, everybody build a little bit more inventory, if you know you have a lot of clients coming. But the main thing in wholesale is that we go broad. There are very few that would not like to try out new products even if they are not your biggest customer today. That's how the world works. So you could say, addressable market on wholesale is, of course, much bigger, and therefore, you can generate higher growth rates short term in wholesale Hearing Aids than you can in retail. Retail is a more natural flow. And if you sell more Reveals, you sell less on something else in a period. So that more represents the organic growth in that business. These 2 things come very well in line over time. There can be a little bit of sell-in stocking effect -- not stocking effect, but much less effect than when you go broad in an independent wholesale market. And just on your question, if I get it right on the second one, all talks about 2027 is too early to go into. We don't want to do that here today, maybe at a later stage. But for 2026, I just think all in all, putting it all together, we just had to declare that a year within the normal. It started with a bit of headwind. Currently, we see some tailwind. There's always been product introduction, part of building fluctuations quarter-by-quarter and month-by-month. But when we get the full half year, I think we have a good representation of the underlying growth in the market. And I am under the opinion that eventually, you will always see the 4% to 6% that comes from underlying demographics come back in unless things kept on getting worse. And as they are not, then it is natural that we start to see some normalization of the global Hearing Aids market.

Julien Ouaddour analyst
#12

Perfect, thank you.

Søren Nielsen executive
#13

Thank you.

Operator operator
#14

The next question comes from the line of Andjela Bozinovic with BNP Paribas.

Andjela Bozinovic analyst
#15

Hi good afternoon. Thank you for taking my questions. I'll stick to 2 as well. The first one would be on the guidance. So can you please discuss what underpins this conservatism of the new guide, which at the midpoint implies 5% growth in Q4? I understand the comps are getting harder with like 200 basis points, but we have around 500 basis points of deceleration in the guide implied. So that is the first question. The second one would be just on the Oticon Reveal trends. So what have you seen in October, if you can just comment on the stocking? Are you seeing less of the launch momentum that helped Q3 wholesale growth or that momentum persists into October?

Søren Nielsen executive
#16

I will put them more or less together. The guidance we built is, of course, our best judgment on the last quarter. And there is still left uncertainty when it comes to market development and you would say the ultimate competitive rebalancing of the situation after all have launched. We are off to a very good start in Q3. We see good response to the product in the market. And this, together with the comps, et cetera, across all 3 business areas is what's built into the guidance. So there is a variation around it, and that is our best take at current that this is where the full year will end. Oticon Reveal, we cannot comment on October isolated, but we can say that we have received a stronger feedback confirmation that the product is also doing really well when being fitted. And I think that's what we can share here today and have shared also in the interim statement.

Andjela Bozinovic analyst
#17

Thank you.

Operator operator
#18

The next question comes from the line of Giang Nguyen with Citi.

Giang Nguyen analyst
#19

Thank you for taking my questions. I have 2, please. The first question is around early Q4 market trends. Is there any comments you can make on how the Hearing Aids market has been trending so far and perhaps break it out in terms of market units as well as ASP? And then my second comment is, I appreciate that you have provided some color around feedback on Reveal, but is there any statistics or any quantification that you can provide to illustrate how the uptake is trending versus either previous generation or versus competitive products in the market? Any comments you can have on price premium as well on Reveal?

Søren Nielsen executive
#20

We simply have no statistics. So the answer to your first question is no, we have no visibility to market development in October. And that's also why one should be careful about commenting on Reveal. So we cannot share any more color than we did. We're talking about positive reception by customers and good fitting results and in general, a good mood around the product. We don't have any statistics or others we can share at this stage. You had a little follow-up question on pricing. We have confirmed before that there is a natural, I would say, price adjustment or increase of pricing, reflecting the level of innovation we bring forward as well as natural catch-up with inflation around the world.

Operator operator
#21

Ms. Giang, have you finished with your questions?

Giang Nguyen analyst
#22

Yes.

Operator operator
#23

The next question comes from the line of Martin Brenoe with Nordea.

Martin Brenoe analyst
#24

I have a question for Rene, please. Given that you have quite a strong top line momentum at the moment, can you maybe give us a little of color on how you are reinvesting those money and whether you are planning for some slowdown into '27 and therefore, holding back a bit or whether you're giving it as much as you can in terms of the commercial momentum that you're seeing at the moment, please?

René Schneider executive
#25

Martin, so I will refrain from commenting into '27. I think we're not at that stage yet. But as I think we also write in the report, when we grow like we do, we have significant operating leverage in the business and increased profitability despite the fact that we do continuously reinvest into the business when it comes to innovation, acquisitions, general infrastructure. The reason why we are still, say, overall at a modest operating expense growth is because all of that reinvestment into the business is coupled with an also strong effort to take cost out on the other side, and that's what's reflected in our cost effectiveness program. So all in all, we feel that you can say we can both invest in the business whilst deliver on margin expansion at the same time and provide a modest growth in operating expenses overall. So that's the balance we try to achieve and essentially nothing new in that.

Operator operator
#26

The next question comes from the line of Kavya with UBS.

Kavya Deshpande analyst
#27

My first one was, again, just around market growth. So just around the underlying volume acceleration from 3% to 5% ex-product launches. I guess, do you have any commentary on what drove this, especially as a lot of the market improvement so far this year has been ASP-driven as opposed to volume acceleration? And then my second question was just around the trend that you've spoken about again with the market in the U.S. self-pay channel about it potentially benefiting from a sort of managed care patient mix shift into that channel. How much of a runway do you see for this to continue from here?

Søren Nielsen executive
#28

Yes, I think the market growth returning to normalized growth levels, we are in Q3 in reality, annualizing the uncertainty that change in administration in U.S. led to. And it was the U.S. commercial market and U.S. market in general, where we saw things go down in speed. But again, the underlying structural growth rate is stable. So eventually, unless things get worse, then it will return to normal growth rate. And I think that is the most likely overall conclusion that we are starting to see the structural growth rate return into the growth numbers. We are, you can say, in absolute numbers, definitely at a smaller market than you would have anticipated, but the growth returns and this is reflecting the underlying structure level. And then managed care versus private, yes, we continue to see the managed care market in the U.S. decline or shrink, have negative growth. And I think that there are many routes to that, but the main cause is that a number of health care plans reduce eligibility. Some then choose to buy themselves, either in a big box retail where they can also find pricing maybe similar to what they would have paid through the insurance company or they go private to a local individual dispenser or into a big retail like ourselves. And this is part of continue to build some growth into the commercial independent segment. And is it any bigger in Q3 than in Q2 or Q1? No. Is this a trend that's likely to continue? Yes, I would find some likelihood that we don't see a change in that. But it's not something I'm on top of, and it's still left with some uncertainty, but it is more arrow down than arrow up for managed care U.S. That's at least our take for now. So Demant in general, being well positioned to the way the U.S. market develops, which is also reflected, I think, in our performance.

Operator operator
#29

The next question comes from the line of Jack Reynolds-Clark with Morgan Stanley.

Jack Reynolds-Clark analyst
#30

I've got 2, please. The first is on wholesale. Could you break down or give an indication, I guess, to the relative contribution of unit growth versus ASP within that wholesale growth number, and kind of the relative contributions of Reveal versus Zeal versus kind of the rest of the portfolio? And then just on Zeal pricing, has your thinking developed or changed around how you're approaching the rollout of additional price points in Zeal? And if so, kind of where is that playing out already and what are your plans for next year?

Søren Nielsen executive
#31

I can only say and reiterate what we write that we also in unit growth have growth above the market growth. We cannot comment any closer than that, but it means that it's meaningful and that the ASP component is also meaningful in that equation. So they are both contributors and significant contributors to the growth. It is, of course, a lot of Zeal and Reveal that drives the momentum in the business and therefore, also the organic growth. No doubt about that. Reveal hits into still what remains to be the majority of the market behind-the-ear RIC solutions. And again, absolute key in a market like U.S. to have kind of flagship products that are considered among the very best that does drive growth. So yes, a lot of it comes from also Reveal. But remember, we only did it in August. So of course, there's also a meaningful contribution from Zeal as we have seen also throughout the first half of the year. Price points, and additional price points, we have said earlier that it's very market specific because it depends on what you call more mid-market volume, and there's huge differences between illustrative examples, U.S. where the premium segment is the biggest and most important, a little opposite in Germany, where the actual volume in the premium segment is yes, limited around 10% on a good day. And if India products are then between 10% or 15%, then it's a relatively small market where in more mid-market, you see much more bulk of the business. And therefore, it has had a meaningful contribution to the unit development to also in Germany, as an example, introduce an additional price point, whereas we have not yet have had no plans currently to do it in U.S., North America. So very market-specific decisions depending on the structure of the market and therefore, the potential and relevance in individual markets.

Operator operator
#32

The next question comes from the line of Susannah Ludwig with Bernstein.

Susannah Ludwig analyst
#33

I have 2, please. I guess first on the strong U.S. private pay market, do you think the recent shutdowns of larger OTC players like Lexi and HLT are helping support growth in this market? And then second, on the stocking dynamics from new products, to what extent did independents hold inventory? And then with the Philips 9060 launch was announced at the end of October, were you benefiting from stocking there in Q3? Or is that a stocking benefit that you might see in Q4?

Søren Nielsen executive
#34

On the private pay OTC, no, I don't see these things correlate at all. It was a very small volume in that market. And I would not find it likely people jump from the consideration to buy an OTC and then buy top of the line, which Reveal is and what everybody introduced right now. So no, I don't see that as a significant contributor to the growth. Does independent hold inventory? It depends a lot. Some do if they assure they are going to fit it and feel comfortable around that. Sometimes you also commit to giving a certain purchase over time and therefore, get conditions. But in general, you don't hold a lot of inventory relative to your business lines. And further stocking up from introductions in Costco, then no, not in Q3.

Operator operator
#35

The next question comes from the line of Martinien Rula with Jefferies.

Martinien Rula analyst
#36

This is Martinien from Jefferies. I would have 2, please. And the first one would be actually on the gross margin. So you had posted 77.1% in H1. You've made a comment about being very happy about the gross margin development into Q3. I would just love to hear you commenting and actually help us understand the underlying drivers of that gross margin improvement. And if you could split this improvement between stronger product mix versus the structural margin improvement from KIND, that would be amazing.

René Schneider executive
#37

Yes. So we are extremely happy with the development on the gross margin, and it is when we upgraded beyond our expectations. And I would say not to quantify, but to, let's say, give an order of importance, it is the organic growth of the Hearing Aids business that is the main driver, followed by KIND, and the consolidation and the share of wallet conversion there. And then lastly, more technically, just in Q3 isolated, we had the tariff refund just to complete the picture. But I would say that's the order of magnitude.

Martinien Rula analyst
#38

Okay. No, that's perfect. And the second question would actually be on France, if that's okay with you. So you've called out a strong market development into Q3. Curious to hear what strong means in that case given the significant growth we had in this market last year. And also, I would be keen on having some thoughts on how you're seeing the development of this market, sorry into Q4, given the huge wave of strikes we have currently in the country.

René Schneider executive
#39

I would say it's relatively well in line with what we stated for the European market in general, the French development and also in France coming back to when there is inventory and no inventory, there is actually a little more tradition for that. So back to Martin's original question that it's not just the U.S. effect, this estimated stocking, there is also other countries where that could be an effect. But I think on the wholesale level, we have seen a good and solid France throughout the year, and Q3 is also a testament to that.

Operator operator
#40

[Operator Instructions] The next question is a follow-up question from the line of Ouaddour, Bank of America.

Julien Ouaddour analyst
#41

I don't want to move anything from the CMD later this month. But a key question we've been asked by investors after such a strong run for Zeal in 2026, and as comps get pretty tough for next year, I mean, is it possible for Zeal to grow on top next year? And then just for this, do you need to expand into new countries? Do you need to accelerate the bullet price point coverage that you were discussing earlier? Or do you feel you need an extension of the clinical addressable market for the product? So, yeah, I would like to get your thoughts on that.

Søren Nielsen executive
#42

Have to be careful with too many details on '27, I would say that's premature. But in general, we, of course, want to grow the business next year. And growing the business is a combination of getting new customers, getting full year effects of the customers you gained through the year, and there are both channels and customers that did not start at January 1. We will continue to do our promotions. We have a pretty good visibility to all introductions now from competitors. So the way things look now, of course, we will build a plan where we also in the future, we will be able to take share.

Operator operator
#43

Ladies and gentlemen, there are no further questions at this time. I'll now pass the floor over to management for any closing comments. Thank you.

Peter Pudselykke executive
#44

Thank you so much, operator, and thanks to everybody for joining us here today. As always, we'll be on the road in the coming weeks, and I do look forward to seeing you there. Have a good rest of the day.

Operator operator
#45

Ladies and gentlemen, the conference has now concluded, and you may disconnect your telephone. Thank you for calling and have a pleasant day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Demant A/S transcript - plus 261,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Demant A/S earnings transcripts and 261,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $145 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.